Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside

Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy

(2019) Moyuka Irimada et al.   JOURNAL OF DERMATOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway

(2019) Romi Gupta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRAF targeting sensitizes resistant melanoma to cytotoxic T cells

(2019) Cigdem Atay et al.   CLINICAL CANCER RESEARCH

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

(2018) Liqin Wang et al.   CELL

Combined BRAF and HSP90 inhibition in patients with unresectableBRAFV600E mutant melanoma

(2018) Zeynep Eroglu et al.   CLINICAL CANCER RESEARCH

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

(2018) Richard D. Carvajal et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy

(2018) Taku Fujimura et al.   JOURNAL OF DERMATOLOGY

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

(2018) Rodabe N Amaria et al.   LANCET ONCOLOGY

Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis

(2018) Yusuke Muto et al.   MELANOMA RESEARCH

BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma

(2018) Julia C. Chisholm et al.   PEDIATRIC BLOOD & CANCER

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells

(2018) Eva Hajek et al.   Oncotarget

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

(2018) Meghan J. Mooradian et al.   OncoImmunology

Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer

(2018) Taku Fujimura et al.   Frontiers in Oncology

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers

(2018) Robert Roskoski   PHARMACOLOGICAL RESEARCH

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

(2018) Joseph I. Clark et al.   Journal for ImmunoTherapy of Cancer

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF -mutated melanoma and other advanced malignancies

(2018) Minny Bhatty et al.   CANCER

BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials

(2018) Taku Fujimura et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

(2018) Praveen K. Bommareddy et al.   Science Translational Medicine

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma

(2018) Sébastien Corre et al.   Nature Communications

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

(2017) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

(2017) Stuart J. Gallagher et al.   INTERNATIONAL JOURNAL OF CANCER

Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling

(2017) Sadanori Furudate et al.   JOURNAL OF DERMATOLOGY

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma

(2017) Renier Heijkants et al.   Oncotarget

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study

(2017) Yousef Zakharia et al.   Oncotarget

Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study

(2016) GA McArthur et al.   ANNALS OF ONCOLOGY

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

(2016) J. Madore et al.   CLINICAL CANCER RESEARCH

Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity

(2016) Taku Fujimura et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

(2016) Asim Amin et al.   Journal for ImmunoTherapy of Cancer

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

(2015) Stephen Mok et al.   BMC CANCER

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients

(2015) Kaori Sakaizawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

(2015) Jean Jacques Grob et al.   LANCET ONCOLOGY

RAF inhibitors that evade paradoxical MAPK pathway activation

(2015) Chao Zhang et al.   NATURE

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

(2015) Blanca Homet Moreno et al.   OncoImmunology

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

(2014) J.-J. Grob et al.   ANNALS OF ONCOLOGY

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

(2014) Chang Xia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations

(2014) E. R. Plimack et al.   INVESTIGATIONAL NEW DRUGS

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

(2014) Dennie T. Frederick et al.   PLoS One

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma

(2013) Xinqi Wu et al.   PLoS One

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

(2012) Kavitha Gowrishankar et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells

(2010) Pramod P. Mehta et al.   CANCER LETTERS

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH